7,275 Shares in Intuitive Surgical, Inc. (NASDAQ:ISRG) Acquired by Wellington Shields Capital Management LLC

Wellington Shields Capital Management LLC bought a new stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 7,275 shares of the medical equipment provider’s stock, valued at approximately $3,236,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Indiana Trust & Investment Management CO increased its holdings in shares of Intuitive Surgical by 5.3% during the 2nd quarter. Indiana Trust & Investment Management CO now owns 500 shares of the medical equipment provider’s stock worth $222,000 after purchasing an additional 25 shares during the period. Hoxton Planning & Management LLC increased its stake in Intuitive Surgical by 4.9% during the second quarter. Hoxton Planning & Management LLC now owns 534 shares of the medical equipment provider’s stock valued at $238,000 after acquiring an additional 25 shares during the period. First Affirmative Financial Network raised its holdings in Intuitive Surgical by 2.7% in the 2nd quarter. First Affirmative Financial Network now owns 996 shares of the medical equipment provider’s stock valued at $443,000 after acquiring an additional 26 shares in the last quarter. Advance Capital Management Inc. lifted its position in shares of Intuitive Surgical by 3.8% in the 1st quarter. Advance Capital Management Inc. now owns 740 shares of the medical equipment provider’s stock worth $295,000 after acquiring an additional 27 shares during the period. Finally, Perigon Wealth Management LLC increased its position in shares of Intuitive Surgical by 0.5% during the first quarter. Perigon Wealth Management LLC now owns 5,363 shares of the medical equipment provider’s stock valued at $2,140,000 after purchasing an additional 27 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on ISRG. Morgan Stanley lifted their price target on shares of Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. JPMorgan Chase & Co. lifted their target price on shares of Intuitive Surgical from $475.00 to $495.00 and gave the company an “overweight” rating in a research report on Friday, July 19th. Redburn Atlantic raised shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and increased their price target for the stock from $380.00 to $510.00 in a research report on Friday, August 2nd. Barclays raised their price target on shares of Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a research note on Thursday, July 18th. Finally, Piper Sandler upped their price objective on Intuitive Surgical from $490.00 to $495.00 and gave the company an “overweight” rating in a research note on Friday, July 19th. Six analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $446.45.

Intuitive Surgical Stock Performance

ISRG traded down $1.64 during midday trading on Friday, hitting $475.05. The company had a trading volume of 31,844 shares, compared to its average volume of 1,508,889. Intuitive Surgical, Inc. has a twelve month low of $254.85 and a twelve month high of $493.97. The firm’s 50-day simple moving average is $458.20 and its 200-day simple moving average is $417.34. The company has a market capitalization of $168.50 billion, a PE ratio of 86.05, a P/E/G ratio of 5.43 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The business had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. During the same quarter last year, the business posted $1.18 earnings per share. Intuitive Surgical’s revenue for the quarter was up 14.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

Insider Transactions at Intuitive Surgical

In related news, EVP Robert Desantis sold 188 shares of the firm’s stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $482.21, for a total value of $90,655.48. Following the transaction, the executive vice president now owns 5,506 shares in the company, valued at $2,655,048.26. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Intuitive Surgical news, SVP Henry L. Charlton sold 40,243 shares of the company’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the sale, the senior vice president now owns 3,001 shares in the company, valued at approximately $1,461,006.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Robert Desantis sold 188 shares of the stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $482.21, for a total value of $90,655.48. Following the completion of the transaction, the executive vice president now directly owns 5,506 shares in the company, valued at approximately $2,655,048.26. The disclosure for this sale can be found here. Insiders sold a total of 51,656 shares of company stock worth $24,700,644 over the last 90 days. 0.90% of the stock is owned by insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.